Capivasertib

Generic Name: Capivasertib

Brand Names: Truqap

Drug Type: Small Molecule

Chemical Formula: C_₂₁H_₂₅ClN_₆O_₂

CAS Number: 1143532-39-1

Unique Ingredient Identifier: WFR23M21IE

Background: Capivasertib has been investigated for the treatment of Metastatic Breast Cancer.

Associated Conditions: -

Associated Therapies: -

Clinical Trials

Study to Assess the Effect of Food and Acid Reducing Agents on the Absorption of Capivasertib in Healthy Participants

Phase 1

Completed

Conditions: Solid and Hematological Malignancies

Interventions: Drug: Capivasertib
Drug: Rabeprazole

First Posted Date: 2021-06-30

Last Posted Date: 2022-05-09

Lead Sponsor: AstraZeneca

Target Recruit Count: 48

Registration Number: NCT04944771

Locations: 🇩🇪
Research Site, Berlin, Germany

Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)

Phase 3

Recruiting

Conditions: Locally Advanced (Inoperable) or Metastatic Breast Cancer

Interventions: Drug: Capivasertib
Drug: Ribociclib
Drug: Abemaciclib
Drug: Fulvestrant
Drug: Palbociclib

First Posted Date: 2021-04-28

Last Posted Date: 2024-12-12

Lead Sponsor: AstraZeneca

Target Recruit Count: 895

Registration Number: NCT04862663

Locations: 🇻🇳
Research Site, Vinh, Vietnam

Capivasertib China PK Study

Phase 1

Completed

Conditions: Advanced Solid Tumours

Interventions: Drug: Capivasertib
Drug: Paclitaxel

First Posted Date: 2021-02-05

Last Posted Date: 2022-08-19

Lead Sponsor: AstraZeneca

Target Recruit Count: 16

Registration Number: NCT04742036

Locations: 🇨🇳
Research Site, Shanghai, China

A Study to Assess How Itraconazole Affects the Uptake and Elimination of Capivasertib in the Body

Phase 1

Completed

Conditions: Healthy Volunteers (Intended Indication: Metastatic Patients With Triple Negative or HR+ Breast Cancer, or Hormone Sensitive Prostate Cancer)

Interventions: Drug: Capivasertib
Drug: Itraconazole

First Posted Date: 2021-01-15

Last Posted Date: 2021-04-09

Lead Sponsor: AstraZeneca

Target Recruit Count: 11

Registration Number: NCT04712396

Locations: 🇩🇪
Research Site, Berlin, Germany

A Phase 1b Study of T-DXd Combinations in HER2-low Advanced or Metastatic Breast Cancer

Phase 1

Active, not recruiting

Conditions: Metastatic Breast Cancer

Interventions: Drug: Trastuzumab deruxtecan
Drug: Durvalumab
Drug: Fulvestrant
Drug: Capecitabine
Drug: Capivasertib
Drug: Anastrozole
Drug: Paclitaxel

First Posted Date: 2020-09-21

Last Posted Date: 2024-11-25

Lead Sponsor: AstraZeneca

Target Recruit Count: 138

Registration Number: NCT04556773

Locations: 🇨🇳
Research Site, Taoyuan, Taiwan

Capivasertib+Abiraterone as Treatment for Patients With Metastatic Hormone-sensitive Prostate Cancer and PTEN Deficiency

Phase 3

Active, not recruiting

Conditions: Hormone-Sensitive Prostate Cancer

Interventions: Other: Placebo
Drug: Capivasertib
Drug: Abiraterone Acetate

First Posted Date: 2020-07-30

Last Posted Date: 2024-12-17

Lead Sponsor: AstraZeneca

Target Recruit Count: 1012

Registration Number: NCT04493853

Locations: 🇻🇳
Research Site, Ho Chi Minh, Vietnam

Testing AZD5363 as a Potential Targeted Treatment in Cancers With AKT Genetic Changes (MATCH-Subprotocol Y)

Phase 2

Active, not recruiting

Conditions: Advanced Lymphoma
Advanced Malignant Solid Neoplasm
Refractory Lymphoma
Hematopoietic and Lymphoid Cell Neoplasm
Refractory Malignant Solid Neoplasm
Refractory Multiple Myeloma

Interventions: Drug: Capivasertib

First Posted Date: 2020-06-19

Last Posted Date: 2024-11-07

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 35

Registration Number: NCT04439123

Locations: 🇺🇸
ECOG-ACRIN Cancer Research Group, Philadelphia, Pennsylvania, United States

Capivasertib+Fulvestrant vs Placebo+Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic HR+/HER2- Breast Cancer

Phase 3

Active, not recruiting

Conditions: Locally Advanced (Inoperable) or Metastatic Breast Cancer

Interventions: Drug: Fulvestrant
Drug: Capivasertib
Drug: Placebo

First Posted Date: 2020-03-12

Last Posted Date: 2023-05-30

Lead Sponsor: AstraZeneca

Target Recruit Count: 818

Registration Number: NCT04305496

Locations: 🇬🇧
Research Site, Sutton, United Kingdom

A Multi-centre Study to Assess the Safety, Tolerability, and Pharmacokinetics of Capivasertib (AZD5363) in Combination With Novel Agents in Patients With Metastatic Prostate Cancer

Phase 1

Completed

Conditions: Prostate Cancer

Interventions: Drug: Capivasertib
Drug: Enzalutamide
Drug: Abiraterone

First Posted Date: 2019-09-12

Last Posted Date: 2022-07-13

Lead Sponsor: AstraZeneca

Target Recruit Count: 27

Registration Number: NCT04087174

Locations: 🇪🇸
Research Site, Barcelona, Spain

Capivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBC

Phase 3

Active, not recruiting

Conditions: Triple Negative Breast Neoplasms

Interventions: Drug: Capivasertib
Drug: Placebo
Drug: Paclitaxel

First Posted Date: 2019-06-25

Last Posted Date: 2024-10-04

Lead Sponsor: AstraZeneca

Target Recruit Count: 923

Registration Number: NCT03997123

Locations: 🇻🇳
Research Site, Ho Chi Minh, Vietnam

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy